Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Days Sales Outstanding : 74.14 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Sonoma Pharmaceuticals Days Sales Outstanding?

Sonoma Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was $2.55 Mil. Sonoma Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $3.14 Mil. Hence, Sonoma Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 74.14.

The historical rank and industry rank for Sonoma Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

SNOA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.93 Med: 55.19 Max: 75.88
Current: 73.58

During the past 13 years, Sonoma Pharmaceuticals's highest Days Sales Outstanding was 75.88. The lowest was 39.93. And the median was 55.19.

SNOA's Days Sales Outstanding is ranked worse than
51.35% of 999 companies
in the Drug Manufacturers industry
Industry Median: 72.15 vs SNOA: 73.58

Sonoma Pharmaceuticals's Days Sales Outstanding stayed the same from Dec. 2022 (74.14) to Dec. 2023 (74.14).

Sonoma Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Sonoma Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Days Sales Outstanding Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Days Sales Outstanding

Get a 7-Day Free Trial

48.28

75.88

66.41

75.34

68.47

Sonoma Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															74.14	73.71	66.71	77.88	74.14

Competitive Comparison of Sonoma Pharmaceuticals's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonoma Pharmaceuticals's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Days Sales Outstanding falls into.

Sonoma Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Sonoma Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

	Days Sales Outstanding (A: Mar. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )	/	Revenue (A: Mar. 2023 )	*	Days in Period
=	( (2.407	+	2.572)	/	2 )	/	13.272	*	365
=	2.4895					/	13.272	*	365
=	68.47

Sonoma Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (2.223	+	2.876)	/	2 )	/	3.138	*	365 / 4
=	2.5495					/	3.138	*	365 / 4
=	74.14

Sonoma Pharmaceuticals (NAS:SNOA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Sonoma Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

O8Z3:Germany

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Executives

Chad Norman White	officer: Interim CFO	645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch	officer: Chief Financial Officer	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly	officer: Interim CEO	1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford	director, officer: CEO and Interim CFO	C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer	director	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz	director, officer: Chief Operating Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid	officer: Chief Strategy/Mkt Officer	OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey	officer: Exec. VP of Res & Devlpment	C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison	director	OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin	director	OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish	other: Officer of Subsidiary (1)	RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954